AlloVir Overview

  • Founded
  • 2013
Founded
  • Status
  • Public
  • Employees
  • 21
Employees
  • Stock Symbol
  • ALVR
Stock Symbol
  • Share Price
  • $30.52
  • (As of Friday Closing)

AlloVir General Information

Description

AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.

Contact Information

Website
Formerly Known As
ViraCyte, AdCyte
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 139 Main Street
  • Suite 500
  • Cambridge, MA 02142
  • United States
+1 (617) 000-0000

AlloVir Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AlloVir Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$30.52 $34.53 $18.15 - $48.96 $1.89B 61.9M 290K -$2.59

AlloVir Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 2,001,178 2,001,178
Revenue 0 0 165 1,135
EBITDA (71,041) (71,041) (25,885) (2,486)
Net Income (69,784) (69,784) (23,839) (2,430)
Total Assets 370,821 370,821 139,422 25,319
Total Debt 8,692 8,692 11,759 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AlloVir Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AlloVir‘s full profile, request access.

Request a free trial

AlloVir Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore AlloVir‘s full profile, request access.

Request a free trial

AlloVir Executive Team (15)

Name Title Board Seat Contact Info
David Hallal Chief Executive Officer & Chairman
Vikas Sinha President, Chief Financial Officer & Board Member
Brett Hagen Chief Accounting Officer, Accounting
Ann Leen Ph.D Chief Scientific Officer & Founder
Ercem Atillasoy Chief Regulatory and Safety Officer
You’re viewing 5 of 15 executive team members. Get the full list »

AlloVir Board Members (11)

Name Representing Role Since
Ansbert Gadicke AlloVir Board Member 000 0000
Ansbert Gadicke MD Self Board Member 000 0000
David Hallal AlloVir Chief Executive Officer & Chairman 000 0000
Diana Brainard Self Board Member 000 0000
Jeffrey Bornstein Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

AlloVir Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AlloVir Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AlloVir‘s full profile, request access.

Request a free trial